Hallak JEC
Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
ArticleAyahuasca
Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis: A Single-Blind Feasibility Proof-of-Concept Trial.
ArticleIbogaine
Ibogaine as a double-edged sword: Developmental cardiotoxicity and neurobehavioral alterations in zebrafish.
ArticleIbogaine
Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study.
ArticlePsilocybin
Classic psychedelics and personality: An updated systematic review.
ArticleKetamine
Safety and tolerance of oral ketamine: A systematic review.
ArticleAyahuasca
Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review.
ArticleAyahuasca
Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats.
ArticleAyahuasca
Clinical pharmacology of ayahuasca: potential applications and future considerations.
ArticlePsilocybin
Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.
ArticleAyahuasca
Acute suicidal behavior following ayahuasca ingestion in a clinical trial setting: a case report.
ArticleAyahuasca
Ayahuasca: pharmacology, safety, and therapeutic effects.
ArticleAyahuasca
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
ArticleKetamine
Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.
ArticleAyahuasca
Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial.
ArticleAyahuasca
Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users.
ArticleKetamine
Solvent-free parallel artificial liquid membrane extraction for drugs of abuse in plasma samples using LC-MS/MS.
ArticleAyahuasca
Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub> receptors.
ArticlePsychedelics
Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.
ArticleAyahuasca
Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial.
ArticlePsychedelics
Hallucinations and Hallucinogens: Psychopathology or Wisdom?
ArticlePsychedelics
Classical Hallucinogens As Antidepressant Drugs: A Cautionary Approach.
ArticleIbogaine
Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences.
ArticleAyahuasca
Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior.
ArticleAyahuasca
Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.
ArticlePsilocybin
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.
ArticleAyahuasca
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability.
ArticleAyahuasca
Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials.
ArticlePsilocybin
Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.
ArticleAyahuasca
Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies.
ArticlePsilocybin
Psychedelic Medicines in Major Depression: Progress and Future Challenges.
ArticleAyahuasca
Essential oil-based dispersive liquid-liquid microextraction for the determination of N,N-dimethyltryptamine and β-carbolines in human plasma: A novel solvent-free alternative.
ArticleAyahuasca
Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial.
ArticlePsilocybin
Polypharmacology or "Pharmacological Promiscuity" In Psychedelic Research: What Are We Missing?
ArticleAyahuasca
Stability Evaluation of DMT and Harmala Alkaloids in Ayahuasca Tea Samples.
ArticleAyahuasca
Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination.
ArticlePsilocybin
Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
ArticlePsilocybin
Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.
ArticlePsilocybin
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.
ArticlePsilocybin
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
ArticleAyahuasca
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
ArticlePsilocybin
Psychedelics and Personality.
ArticleAyahuasca
Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities.
ArticleAyahuasca
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.
ArticlePsilocybin